Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05283759

UZ Brussel HRMC Registry of Brugada Syndrome

The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome at UZ Brussel hospital (UZB).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Brugada Syndrome Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heart Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UZ Brussel Heart Rhythm Management Center

Brussels, 1090, Belgium

Location status: Recruiting

Location contact

Carlo de Asmundis, MD, PhD

CONTACT

[email protected]

+32024763704

About this study

The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome.

These includes:

  • demographical data: age, sex
  • antropometric data: height, weight, BMI
  • clinical data: comorbidities, arrhythmias, PM or ICD implantation, therapy
  • data on the families: number of family members, sudden death history. 4) data on the genetics 5) data on: ECG, echocardiography, CT scan, MRI of heart, MRI of brain, ECG imaging, 3D electroanatomical mapping and ablation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Brugada syndrome diagnosis

Exclusion criteria

  • Other diagnosis different from Brugada syndrome

Treatment and study plan

No intervention because it is a patient registry

Other

Primary outcomes

  1. Ventricular arrhythmias

    Time frame: through study completion, an average of 10 year

    Composite of: sudden cardiac death, aborted sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, ICD appropriate therapy

  2. Atrial fibrillation

    Time frame: through study completion, an average of 10 year

    Atrial fibrillation occurrence

  3. Death for any cause

    Time frame: through study completion, an average of 10 year

    Death for any cause

  4. Cardiovascular death

    Time frame: through study completion, an average of 10 year

    Death for cardiovascular cause

  5. Genetic mutations

    Time frame: Baseline

    Genetic mutations (pathogenic and variant of unknown significance) associated with Brugada syndrome. Wide gene panel with next generation sequencing will be used: Roche SeqCap® EZ Human Exome Probes v3.0 for BrS.

Study contacts

Contact information is provided by the study sponsor or research team.

Carlo de Asmundis, MD, PhD

CONTACT

[email protected]

+32024763704

Sponsors and collaborators

Lead sponsor

Universitair Ziekenhuis Brussel

Other

Registry information

Official study title

UZ Brussel Heart Rhythm Management Center Monocentric Registry of Brugada Syndrome

Acronym: HRMCBrS

Important dates

Study start
1992
Primary completion
2032
Study completion
2032
First posted
Mar 17, 2022
Registry last updated
Mar 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.